Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 6:21 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 1,144 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Grippe Clear all

Conditions: Influenza, Human, COVID-19, Influenza A, Influenza B, Respiratory Syncytial Virus (RSV)
Interventions: Not listed
Lead sponsor: Evidation Health; Industry
Eligibility: 18 Years and older
Enrollment: 18,157 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: San Mateo, California

Conditions: Influenza, Human, Pregnancy, Birth Defect
Interventions: Flucelvax Trivalent Influenza Vaccine, Flucelvax Quadrivalent Influenza Vaccine; Biological
Lead sponsor: Seqirus; Industry
Eligibility: Female only
Enrollment: 692 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Wilmington, North Carolina

Conditions: Influenza
Interventions: GSK Biologicals' investigational vaccine GSK2590066A, GSK Biologicals' investigational vaccine GSK2592984A, GSK Biologicals' investigational vaccine GSK2340274A, GSK Biologicals' investigational vaccine GSK2340273A, Placebo; Biological · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 521 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 4
States / cities: Anaheim, California • Stockbridge, Georgia • Lenexa, Kansas + 1 more

Conditions: Influenza
Interventions: Fluzone, Fluad; Biological
Lead sponsor: Yale University; Other
Eligibility: 21 Years and older
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Influenza
Interventions: Placebo, Cold-adapted live attenuated influenza virus vaccine, trivalent, Trivalent inactivated influenza vaccine; Other · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 6
States / cities: Washington D.C., District of Columbia • Atlanta, Georgia • St Louis, Missouri + 3 more

Conditions: Immunization; Infection, Transplantation Infection, Influenza, Solid Organ Transplant
Interventions: High Dose Quadrivalent Inactivated Influenza Vaccine, Standard Dose Quadrivalent Inactivated Influenza Vaccine; Biological
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 396 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: H1N1 Influenza Virus
Interventions: H1N1 vaccine high dose, H1N1 vaccine low dose; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 7
States / cities: Atlanta, Georgia • St Louis, Missouri • Winston-Salem, North Carolina + 4 more

Conditions: Influenza, Community-acquired Pneumonia, Cardiovascular Events
Interventions: Adjuvanted Quadrivalent Inactivated Influenza Vaccine (aIIV4), High-Dose Quadrivalent Inactivated Influenza Vaccine (HD-IIV4); Biological
Lead sponsor: Kaiser Permanente; Other
Eligibility: 65 Years and older
Enrollment: 1,500,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Oakland, California

Conditions: Influenza, Influenza Immunisation
Interventions: Influenza Virus Vaccine Inactivated; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Influenza
Interventions: GSK2340274A, GSK2340273A, Seasonal trivalent influenza vaccine (TIV), Saline placebo; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 19 Years to 40 Years
Enrollment: 611 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 4
States / cities: Stockbridge, Georgia • Raleigh, North Carolina • Austin, Texas + 1 more

Conditions: Influenza, Pneumonia
Interventions: oseltamivir; Drug
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years and older
Enrollment: 1,107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 5
States / cities: Louisville, Kentucky

Conditions: Influenza, Virus Diseases
Interventions: H5N1 (6-2) AA ca Recombinant (A/Hong Kong/213/2003 x A/AnnArbor/6/60 ca); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Influenza
Interventions: GSK2340274A, GSK2340273A; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 4,048 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 25
States / cities: Mesa, Arizona • Phoenix, Arizona • Los Angeles, California + 21 more

Conditions: Healthy
Interventions: Trivalent influenza virus vaccine live, intranasal; Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 6 Months to 59 Months
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 16
States / cities: Little Rock, Arkansas • Marietta, Georgia • Bardstown, Kentucky + 13 more

Conditions: Influenza
Interventions: Peramivir; Drug
Lead sponsor: BioCryst Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 15
States / cities: Brooksville, Florida • Lakeland, Florida • Miami, Florida + 12 more

Conditions: Influenza, Human
Interventions: Zanamivir, Placebo to match zanamivir, Oseltamivir, Placebo to match oseltamivir; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 16 Years and older
Enrollment: 626 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 40
States / cities: Birmingham, Alabama • Phoenix, Arizona • Chula Vista, California + 37 more

Conditions: Avian Influenza, Influenza Immunisation
Interventions: A/H7N9, AS03, Phosphate Buffered Saline (PBS) diluent; Biological · Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 19 Years to 70 Years
Enrollment: 304 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 9
States / cities: Atlanta, Georgia • Iowa City, Iowa • Baltimore, Maryland + 6 more

Conditions: Influenza
Interventions: IIV Flu Vaccine, Metronidazole, Neomycin, Vancomycin; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 40 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Influenza
Interventions: Data collection; Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: Female only
Enrollment: 507 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Wilmington, North Carolina

Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Biphenotypic Acute Leukemia, Undifferentiated Leukemia, Prolymphocytic Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia, Myeloproliferative Neoplasm, Relapsed Large Cell Lymphoma, Mantle Cell Lymphoma, Hodgkin Lymphoma, Burkitt Lymphoma, Relapsed T-Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, Relapsed Small Lymphocytic Lymphoma, Relapsed Marginal B-cell Lymphoma, Relapsed Follicular Lymphoma, Lymphoplasmacytic Lymphoma
Interventions: Fludarabine, Melphalan, Total Body Irradiation; Drug · Radiation
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Influenza
Interventions: Fluzone, Flucelvax, Fluzone High-Dose, Fluad; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Pneumococcal Infections
Interventions: V114, QIV, Matching Placebo for V114; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 50 Years and older
Enrollment: 1,200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 45
States / cities: Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 39 more

Conditions: COPD
Interventions: LAIV; Biological
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 40 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Influenza
Interventions: Ca/04/2009/H1N1r Challenge Virus; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Wearable Assisted Viral Evidence (WAVE) Study A Decentralized, Prospective Study Exploring the Relationship Between Passively-collected Data From Wearable Activity Devices and Respiratory Viral Infections

Flucelvax (TIVc or QIVc) Pregnancy Registry

Immunogenicity and Safety of Pandemic Influenza Vaccines in Adults Aged 18 - 49 Years Old

Systems Investigation of Vaccine Responses in Aging and Frailty

Post-Partum Immunization With Live Attenuated Influenza Vaccine (LAIV) or Trivalent Influenza Vaccine (TIV) in Post-Partum Breast Feeding Women

High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients

Safety and Efficacy of an H1N1 Influenza Vaccine in People With Asthma

Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years

Evaluation of Human Immune Responses to Influenza Virus Vaccination in Healthy Volunteers

Safety and Immunogenicity of H1N1 Vaccine With Trivalent Inactivated Seasonal Influenza Vaccine in Adults

Rapid Empiric Treatment With Oseltamivir Study (RETOS)

Single Group Study of the Safety of and Immune Response to a Bird Flu Virus Vaccine (H5N1) in Healthy Adults

Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and Older

A Study to Evaluate the Shedding and Safety of Trivalent Influenza Virus Vaccine Live, Intranasal in Infants and Young Children

Safety, PK and Effectiveness of IV Peramivir in Elderly and Higher Risk Subjects With Uncomplicated Influenza

A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza

2017 A/H7N9 IIV Revaccination

Systems Biology of Flu Vaccine in Healthy Adults With and Without the Use of Antibiotics

Fluarix/ FluLaval/ Fluarix Quadrivalent/ FluLaval Quadrivalent Vaccine Pregnancy Registry

Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies

B Cell and Antibody Response to Seasonal Influenza Vaccines in Younger and Older Adults

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When Administered Concomitantly With Influenza Vaccine in Healthy Adults 50 Years of Age or Older (V114-021/PNEU-FLU)

Responses to Live Attenuated Influenza Virus (LAIV) in Chronic Obstructive Pulmonary Disease (COPD)

Evaluation of Anti-Hemagglutinin (Anti-HA) Antibodies as Protection From the Flu in Healthy People